Association of sodium-glucose cotransporter-2 inhibitors with outcomes in type 2 diabetes with reduced and preserved left ventricular ejection fraction: Analysis from the CVD-REAL 2 study

CVD-REAL Invest Study Grp, Carolyn S. P. Lam*, Avraham Karasik, Cheli Melzer-Cohen, Matthew A. Cavender, Shun Kohsaka, Anna Norhammar, Marcus Thuresson, Hungta Chen, Eric Wittbrodt, Peter Fenici, Mikhail Kosiborod

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

13 Downloads (Pure)


This study of real-world data from the Maccabi database in Israel compared the risk of heart failure hospitalization (HHF) or death in patients with type 2 diabetes (T2D) initiating sodium-glucose cotransporter-2 (SGLT2) inhibitors versus other glucose-lowering drugs (OGLDs) according to baseline left ventricular (LV) ejection fraction (EF). After propensity-matching patients by baseline EF there were 10 614 episodes of treatment initiation; 57% had diabetes for >10 years, the mean glycated haemoglobin level was 66 mmol/mol (8.2%), similar to 43% had cardiovascular disease, similar to 7% had heart failure and similar to 20% had chronic kidney disease. A total of 2876 patients (similar to 9%) had reduced EF (

Original languageEnglish
Number of pages5
JournalDiabetes obesity & metabolism
Publication statusPublished - 23-Mar-2021


  • diabetes
  • ejection fraction
  • heart failure hospitalization
  • mortality
  • real&#8208
  • world evidence

Cite this